semaglutide fda submission Approves Oral as First GLP-1 Pill for Weight Loss FDA accepts filing application for

high blood pressure, fatty liver) Precautions : Not recommended for people with a history of pancreatitis Consult your physician if pregnant or planning pregnancy Possible Side Effects Common : nausea, mild gastrointestinal discomfort, and injection-site reactions

This reflects the biological chronicity of obesity: the hypothalamic set-point for body weight, appetite hormone profiles (including leptin and ghrelin), and resting metabolic rate tend to revert toward pre-treatment baselines once pharmacological GLP-1 stimulation is removed

If GLP-1s are going to be treated like chronic therapies, we need a model that prioritizes durability and simplicitynot just a temporary discount.

If you are still unsure where to begin, we recommend taking our Health Quiz